Search

Your search keyword '"Liu, Wen‐Yue"' showing total 299 results

Search Constraints

Start Over You searched for: Author "Liu, Wen‐Yue" Remove constraint Author: "Liu, Wen‐Yue"
299 results on '"Liu, Wen‐Yue"'

Search Results

1. Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease

3. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients

5. GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

6. OS-054 Validation of the Baveno VII ‘rule of 5’ in a real-life multicentre cohort of patients with metabolic dysfunction associated steatotic liver disease

7. WED-246 A non-invasive index for significant liver fibrosis and stratifying risk of cirrhosis in patients with type 2 diabetes mellitus in primary care

8. Associations between cuprotosis‐related genes and the spectrum of metabolic dysfunction‐associated fatty liver disease: An exploratory study.

9. Clinical Features and Long-Term Outcomes of Patients Diagnosed with MASLD, MAFLD, or Both

10. Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study

11. A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia.

12. Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD‐related liver fibrosis

13. A Population-based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia

14. Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD‐related liver fibrosis.

15. MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease

19. aMAP score and its combination with liver stiffness measurement accurately assess liver fibrosis in virologically suppressed CHB patients

22. A Population-based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia

25. AutoFibroNet: A deep learning and multi‐photon microscopy‐derived automated network for liver fibrosis quantification in MAFLD.

28. Letter: Drug interaction in resmetirom times.

29. SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface

32. Global multi-stakeholder endorsement of the MAFLD definition

33. Global multi-stakeholder endorsement of the MAFLD definition

34. Free Triiodothyronine and Free Triiodothyronine to Free Thyroxine Ratio Predict All-Cause Mortality in Patients with Diabetic Foot Ulcers

36. Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients

37. Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease

40. Machine learning improves significant fibrosis prediction among Asian patients with biopsy proven non-alcoholic fatty liver disease: a report from GO-ASIA working group

43. The interaction of SAMM50-rs738491, PARVB-rs5764455 and PNPLA3-rs738409 increases susceptibility to nonalcoholic steatohepatitis

46. Associations of hydroxysteroid 17-beta dehydrogenase 13 variants with liver histology in Chinese patients with MAFLD

47. Interaction of SAMM50-rs738491, PARVB-rs5764455 and PNPLA3-rs738409 Increases Susceptibility to Nonalcoholic Steatohepatitis

48. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease

Catalog

Books, media, physical & digital resources